

#6

Sheet 1 of 3

Form PTO-1449 U.S. Department of Commerce Patent and Trademark Office INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use several sheets if necessary)</i>	ATTY. DOCKET NO. P1614-7038	SERIAL NO. 08/875,603
	APPLICANT Lukas-Laskey, et al.	
	FILING DATE August 4, 1997	GROUP 1614

U.S. PATENT DOCUMENTS

Examiner Initial	Document Number	Date	Name	Class	Subclass	Filing Date If Appropriate

FOREIGN PATENT DOCUMENTS

Document Number	Date	Country	Class	Subclass	Translation Yes No

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

1	PS	AA	J. of Cardiovascular Pharm; Senior, et al., "Effects of Carvedilol on Ventricular Arrhythmias", 1992, Vol. 19, (Suppl. 1): pp. S117-S121.
2	PS	AB	J. of Cardiovascular Pharm; DasGupta, et al., "The Effects of Intravenous Carvedilol, A New Multiple Action Vasodilatory β -Blocker, in Congestive Heart Failure", 1991, Vol. 18, (Suppl. 1): pp. S12-S16.
3	PS	AE	American J. of Cardiology; DasGupta, et al., "Value of Carvedilol in Congestive Heart Failure Secondary to Coronary Artery Disease", 1990, Vol. 66, pp. 1118-1123.
4	PS	AF	Z. Kardiol; A. Buchwald, et al., "Acute Hemodynamic Effects of the Beta-blocker Carvedilol in Heart Failure", 1990, Vol. 79, No. 6, pp. 424-428.
5	PS	AG	JACC; DiLenarda, et al., "Acute Hemodynamic Effects of Carvedilol Versus Metoprolol In Idiopathic Dilated Cardiomyopathy", 1991, Vol. 17, No. 2, Abstract 142A.
6	PS	AH	Frontiers in CHF; D. Tepper, "Multicenter Oral Carvedilol Heart Failure Assessment", 1996, Vol. 2, No. 1, pp. 39-40.
7	PS	AI	J. of Cardiovascular Pharm; DasGupta, et al., 1992, Vol. 19, (Suppl. 1): pp. S62-S67.
8	PS	AJ	J. of Hypertension; C. Rosendorff, "Beta-blocking agents with vasodilator activity", 1993, Vol. 11, (Suppl. 4): pp. S37-S40.
9	PS	AK	Cardiology; J. Lessem, et al., "Development of a Multi-action Beta-blocker", 1993, Vol. 82, (Suppl. 3): pp. 50-58.
10	PS	AL	Drug Safety; W.J. Louis, et al., "A Risk-Benefit Assessment of Carvedilol in the Treatment of Cardiovascular Disorders", 1994, Vol. 11, No. 2, pp. 86-93.

Payllis Apwack

6/2/98

FORM PTO-1449	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	ATTY. DOCKET NO. P1614-7038	SERIAL NO. 08/875,603
LIST OF REFERENCES CITED BY APPLICANT (Use several sheets if necessary)		APPLICANT LUKAS-LASKEY et al	
		FILING DATE August 4, 1997	GROUP 1614

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NO.	DATE	NAME	CLASS	SUB- CLASS	FILING DATE
PS	AS	5,308,862	5/3/94	OHLSTEIN	514	411	3/5/93
PS	AT	4,888,179	12/19/89	APPELGREN et al	424	480	1/15/88
PS	AU	5,312,828	5/17/94	FINKELSTEIN et al	514	381	8/14/91

OTHER REFERENCES (Including Author, Title, Date, Pertinent Pages, Etc.)

11 ✓ PS	AV	1994 American Heart Association, Inc., "A Randomized Trial of β -Blockade in Heart Failure", <i>Circulation</i> 90(4), October 1994, pp. 1765-1773.
12 ✓ PS	AW	Waagstein et al., The Lancet, vol. 342, December 11, 1993, "Beneficial effects of metoprolol in idiopathic dilated cardiomyopathy", pp. 1441-1446.
13 ✓ PS	AX	Ruffolo et al., Cardiology 1993; 82(suppl 3):24-28, "Cardioprotective Potential of Carvedilol", pp. 24-28.
14 ✓ PS	AY	Feuerstein et al., Journal of Hypertension 1993, Vol. 11(suppl 4), "Myocardial protection by the novel vasodilating beta-blocker, carvedilol; potential relevance of anti-oxidant activity".
15 ✓ PS	AZ	Feuerstein et al., Journal of Cardiovascular Pharmacology, 19(suppl. 1) S138-S141, "Myocardial Protection with Carvedilol" (1992).
16 ✓ PS	BA	DiBianco et al., The New England Journal of Medicine, Vol. 320, March 16, 1989, No. 11, "A comparison of oral milrinone, digoxin, and their combination in the treatment of patients...", pp. 677-83.
17 ✓ PS	BB	Cohn et al., The New England Journal of Medicine, Vol. 313, No. 24, "Effect of vasodilator therapy on mortality in chronic congestive heart failure", June, 1986, pp. 1547-1552.
18 PS	BC	McTavish et al., Drugs, 45 (2): 232-258, 1993, "Carvedilol, A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy".

EXAMINER Phyllis Spivack	DATE CONSIDERED 6/2/98
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

Form PTO-1449	U.S. Department of Commerce Patent and Trademark Office	ATTY. DOCKET NO. P1614-7038	SERIAL NO. 08/875,603
INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use several sheets if necessary)</i>		APPLICANT Lukas-Laskey, et al.	
		FILING DATE August 4, 1997	GROUP 1614

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)
(Continued)

19	PS	AM	Drugs; McTavish, et al., "Carvedilol - A Review of its Pharmacodynamic and Pharmacokinetic Properties, and Therapeutic Efficacy", 1993, Vol. 45, No. 2, pp. 232-258.
20	PS	AN	Circulation; H. Krum, et al., "Effects of Carvedilol, a Vasodilator- β -Blocker, in Patients with Congestive Heart Failure Due to Ischemic Heart Disease", 1995, Vol. 92, No. 2, pp. 212-218.
21	PS	AO	CBS-TV; CBS Evening News, Transcript, Jan. 27, 1993, 6:30-7:00pm.
22	PS	AP	CNBC; Steals and Deals, Transcript, Jan. 29, 1993, 8:30pm.
23	PS	AQ	Circulation; DasGupta, et al., 1989, Vol. 80, No. 4, (Suppl. II): pp. 116-117.
24	PS	AR	Drugs of Today; Ruffolo, et al., "Carvedilol (Kredex): A Novel Multiple Action Cardiovascular Agent", 1991, Vol. 27, No. 7, pp. 465-492.
EXAMINER Phyllis Spivack			DATE CONSIDERED 6/2/98
EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.			